Autoimmune

The multi-year collaboration aims to develop tolerizing vaccines for up to 3 autoimmune diseases.

Martina Porter, MD, FAAD, vice chair of research, Department of Dermatology, Beth Israel Deaconess Medical Center, discusses efficacy and safety findings from a phase 2 study.

The risk for incident autoimmune inflammatory rheumatic disease (AIRD) was greater among patients with a history of COVID-19 infection.

Pregnant female patients with rheumatoid arthritis (RA) treated with methotrexate and leflunomide within 3 months of conception faced an increased possibility of adverse pregnancy outcomes, specifically stillbirth or abortion.

Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of stay (LOS).

Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.

This poster reported that photoprotection management of lupus is unaffordable for some patients, which may have an impact on sunscreen application frequency.

Posters reported the prevalence of autoimmune comorbidities among patients with vitiligo, demonstrating the need for earlier screenings and updated clinical guidelines.

Telehealth, which increased 63-fold from 2019 to 2020, has potential for managing and delivering care to patients with rheumatic diseases.

This analysis uses claims and electronic health records from 2021 to examine racial and ethnic variations in immune-mediated inflammatory diseases in the United States.

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with controls.

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with cutaneous lupus erythematosus (CLE).

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

An observational registry study revealed that inflammatory disease activity is not the only factor influencing the achievement of treatment targets for patients with rheumatoid arthritis (RA).

This year’s most-read articles on autoimmune diseases explored comorbidities with cardiovascular disease, the value of new forms of monitoring and therapy, and more.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).

A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.

A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.

A retrospective analysis reveals that pregnant patients with autoimmune skin diseases have higher risks for adverse pregnancy outcomes.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with Erythrocyte Sedimentation Rate responses.

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990 to 2019.

Results from a retrospective, matched cohort study suggested that valvular heart disease and aortic stenosis may contribute to disparities in cardiovascular disease–related mortality in patients with rheumatoid arthritis (RA).

At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.

A retrospective, population-based study reveals a possible association between COVID-19 infection and autoimmune and autoinflammatory outcomes.